In Vitro and In Vivo Nonimaging Tests
The radioimmunoassay (RIA) method was first developed by S.A. Berson and R.S. Yalow in the late 1950s for the determination of insulin in human serum. Currently, the method is employed extensively to determine numerous hormones, enzymes, antigens, and drugs in minute quantities (10-9-10-12 M) in human plasma in order to assess various disease conditions. The general term for this method in both immune and nonimmune systems is the competitive binding assay (CBA).
KeywordsCellulose Hepatitis Cortisol Heparin Anemia
Unable to display preview. Download preview PDF.
- Andrews JT, Milne MJ. Nuclear Medicine. New York: Wiley; 1977.Google Scholar
- Chase GC, Rabinowitz JL. Principles of Radioisotope Methodology. 3rd ed. Minneapolis: Burgess; 1970.Google Scholar
- Hayes RL, Goswitz FA, Pearson Murphy BE, eds. Radioisotopes in medicine: In vitro studies. CONF-671111. US Atomic Energy Commission, Oak Ridge; 1972.Google Scholar
- Kirkham KD, Hunter WM. Radioimmunoassay Methods. Baltimore: Williams & Wilkins; 1971.Google Scholar
- Moss AJ Jr, Dalrymple GV, Boyd CM, eds. Practical Radioimmunoassay. St Louis: Mosby; 1976.Google Scholar
- Odell WD, Daughaday WH, eds. Principles of Competitive Protein-Binding Assays. Philadelphia: Lippincott; 1974.Google Scholar
- Rothfeld B, ed. Nuclear Medicine In Vitro. Philadelphia: Lippincott; 1974.Google Scholar
- Thorell JI, Larson SM. Radioimmunoassay and Related Techniques. St Louis: Mosby; 1978.Google Scholar